BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29378179)

  • 1. Human GIP(3-30)NH
    Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
    Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GIP(3-30)NH
    Sparre-Ulrich AH; Gabe MN; Gasbjerg LS; Christiansen CB; Svendsen B; Hartmann B; Holst JJ; Rosenkilde MM
    Biochem Pharmacol; 2017 May; 131():78-88. PubMed ID: 28237651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.
    Hansen LS; Sparre-Ulrich AH; Christensen M; Knop FK; Hartmann B; Holst JJ; Rosenkilde MM
    Br J Pharmacol; 2016 Mar; 173(5):826-38. PubMed ID: 26572091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor.
    Yuliantie E; van der Velden WJC; Labroska V; Dai A; Zhao F; Darbalaei S; Deganutti G; Xu T; Zhou Q; Yang D; Rosenkilde MM; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2021 Oct; 192():114715. PubMed ID: 34339714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
    PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model.
    Weaver RE; Donnelly D; Wabitsch M; Grant PJ; Balmforth AJ
    Int J Obes (Lond); 2008 Nov; 32(11):1705-11. PubMed ID: 18779825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.
    Harada N; Yamada Y; Tsukiyama K; Yamada C; Nakamura Y; Mukai E; Hamasaki A; Liu X; Toyoda K; Seino Y; Inagaki N
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E61-8. PubMed ID: 17971513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.
    Sparre-Ulrich AH; Hansen LS; Svendsen B; Christensen M; Knop FK; Hartmann B; Holst JJ; Rosenkilde MM
    Br J Pharmacol; 2016 Jan; 173(1):27-38. PubMed ID: 26359804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
    Ravn P; Madhurantakam C; Kunze S; Matthews E; Priest C; O'Brien S; Collinson A; Papworth M; Fritsch-Fredin M; Jermutus L; Benthem L; Gruetter M; Jackson RH
    J Biol Chem; 2013 Jul; 288(27):19760-72. PubMed ID: 23689510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling.
    Malde AK; Srivastava SS; Coutinho EC
    J Pept Sci; 2007 May; 13(5):287-300. PubMed ID: 17437246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.
    Tseng CC; Kieffer TJ; Jarboe LA; Usdin TB; Wolfe MM
    J Clin Invest; 1996 Dec; 98(11):2440-5. PubMed ID: 8958204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling.
    Tseng CC; Zhang XY
    Endocrinology; 2000 Mar; 141(3):947-52. PubMed ID: 10698169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes.
    Nie Y; Ma RC; Chan JC; Xu H; Xu G
    FASEB J; 2012 Jun; 26(6):2383-93. PubMed ID: 22366643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.
    Deacon CF; Plamboeck A; Rosenkilde MM; de Heer J; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E468-75. PubMed ID: 16608883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.
    Rosenkilde MM; Lindquist P; Kizilkaya HS; Gasbjerg LS
    Peptides; 2024 Jul; 177():171212. PubMed ID: 38608836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
    Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
    J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
    Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
    Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.
    Ceperuelo-Mallafré V; Duran X; Pachón G; Roche K; Garrido-Sánchez L; Vilarrasa N; Tinahones FJ; Vicente V; Pujol J; Vendrell J; Fernández-Veledo S
    J Clin Endocrinol Metab; 2014 May; 99(5):E908-19. PubMed ID: 24512489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.